Klin Onkol 2025; 38(3): 218-223. DOI: 10.48095/ccko2025218.
Background: There is no doubt that PARP inhibitors (PARPi) have significantly improved the prognosis of patients with advanced-stage ovarian cancer. In the history of treatment for this disease, their impact is second only to the introduction of platinum-based chemotherapy. As with any new therapeutic modality, integrating PARPi into routine clinical practice is a complex process. In the Czech Republic, some agents, combinations, or indications are not reimbursed, and indication criteria often require several conditions to be met simultaneously. These factors may lead to uncertainties in the practical use of PARPi. Aim: This article aims to highlight and discuss areas where such uncertainties may arise in clinical practice.